Intelligence / Healthtech / New Clinical Trials / Frontier Medicines Corporation
Clinicaltrial registered18 Nov 2026
Frontier Medicines Corporation
18 Nov 2026: Trial registered · Ph 1/2 Study to Evaluate Safety & Tolerability of FMC-242 Alone and in Combination in Adults With Advanced Solid Tumors. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 18 Nov 2026
- Title
- Ph 1/2 Study to Evaluate Safety & Tolerability of FMC-242 Alone and in Combination in Adults With Advanced Solid Tumors
- Conditions
- Locally Advanced Solid Tumor
- Phase
- Phase 1, Phase 2
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Reference
- NCT07944092
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Frontier Medicines Corporation
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.